Related Experiment Video
Updated: Oct 20, 2025
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Challenges to the Development of the Next Generation of Self-Reporting Cardiovascular Implantable Medical Devices
Insights
New self-reporting cardiovascular implants promise to detect disease early, enabling predictive healthcare. This technology aims to prevent in-stent restenosis and graft failure, improving patient outcomes for heart and vasculature conditions.
Area of Science:
- Biomedical Engineering
- Cardiovascular Medicine
- Medical Device Technology
Background:
- Cardiovascular disease (CVD) is a leading global cause of mortality, often involving narrowed blood vessels.
- Current treatments like percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) can be followed by complications such as in-stent restenosis (ISR) and graft failure.
- There is a critical need for advanced monitoring to prevent these adverse events and improve patient prognosis.
Purpose of the Study:
- To critically review the obstacles hindering the development and implementation of self-reporting cardiovascular stents and grafts.
- To assess the latest research, technological advancements, and current devices in smart cardiovascular implantable biosensors.
- To evaluate the market potential and clinical trial status of these emerging technologies for precision medicine in cardiovascular care.
Main Methods:
- Analysis of current research and technological advancements in cardiovascular implantable biosensors.
- Evaluation of smart stent/graft technologies with wireless sensing, data, and power transfer capabilities.
- Review of devices that have reached clinical trials and assessment of their market potential.
Main Results:
- Development of cardiovascular implants with integrated sensors for real-time monitoring is advancing.
- Smart biosensors and wireless solutions are key components for self-reporting stent/graft technology.
- Several devices have entered clinical trials, indicating progress towards market implementation.
Conclusions:
- Self-reporting cardiovascular implants offer a pathway to precision medicine and predictive healthcare for CVD.
- Overcoming development and regulatory hurdles is crucial for the successful adoption of this technology.
- These advanced implants have the potential to significantly reduce morbidity and mortality associated with cardiovascular interventions by detecting early signs of disease.
Abstract:
Cardiovascular disease (CVD) is a group of heart and vasculature conditions which are the leading form of mortality worldwide. Blood vessels can become narrowed, restricting blood flow, and drive the majority of hearts attacks and strokes. Reactive surgical interventions are frequently required; including percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). Despite successful opening of vessels and restoration of blood flow, often in-stent restenosis (ISR) and graft failure can still occur, resulting in subsequent patient morbidity and mortality. A new generation of cardiovascular implants that have sensors and real-time monitoring capabilities are being developed to combat ISR and graft failure. Self-reporting stent/graft technology could enable precision medicine-based and predictive healthcare by detecting the earliest features of disease, even before symptoms occur. Bringing an implantable medical device with wireless electronic sensing capabilities to market is complex and often obstructive undertaking. This critical review analyses the obstacles that need to be overcome for self-reporting stents/grafts to be developed and provide a precision-medicine based healthcare for cardiovascular patients. Here we assess the latest research and technological advancement in the field, the current devices; including smart cardiovascular implantable biosensors and associated wireless data and power transfer solutions. We include an evaluation of devices that have reached clinical trials and the market potential for their end-user implementation.
